ODAC 30% Off Registration, Use Code: JDD30
Skip to main content
JDD Webinars

What’s New in Acne Management: What We Have Learned from Increased Understanding of Acne Pathophysiology

By October 28, 2020April 21st, 2021No Comments

Featured Article

What's New in Acne Management:

What We Have Learned From Increased Understanding of Acne Pathophysiology

Join Drs. Leon H. Kircik, Linda Stein Gold, and Jonathan S. Weiss as they discuss the medical interventions generally targeting one or more of the key factors contributing to the development of acne lesions: follicular hyperproliferation and abnormal desquamation (topical and oral retinoids, azelaic acid, salicylic acid, hormonal therapy), increase sebum production (oral isotretinoin, hormonal therapy), C. acnes proliferation (benzoyl peroxide, topical and oral antibiotics, azelaic acid) and inflammation (oral isotretinoin, oral tetracyclines, topical retinoids, azelaic acid).

Acne pathogenesis is multifactorial and not clearly understood; a key factor includes genetics and may result as in interplay of release of inflammatory mediators into the skin, follicular hyperkeratinization with subsequent plugging of the follicle, Cutibacterium acne (C. acnes), formerly Propionibacterium acnes or P. acnes, follicular colonization and excess sebum production.

C. acnes has been shown to mediate inflammatory processes at the site of the sebaceous follicle contributing to the formation of free radical species and generating pro-inflammatory cytokines. Excess sebum production and C. acnes colonization lead to the formation of microcomedones leading to the development of open or closed comedones, inflammatory papules, pustules and cysts characteristic of acne.
Acne severity and grade (comedonal, papulopustular, mixed, nodular), skin type, presence of acne scarring and postinflammatory hyperpigmentation, menstrual cycle history (in women), skin current skin care regimen are factors influencing treatment with classes of topical agents include: comedolytic (anticomedogenic), antimicrobial, antibiotic and antiinflammatory; each impact on the four main pathogenic features of acne.

FACULTY


Leon H. Kircik, MD

Clinical Professor of Dermatology
Indiana University School of Medicine
Mount Sinai Medical Center, New York, NY
Physicians Skin Care, PLLC
Louisville, KY


Linda Stein Gold, MD

Director, Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan


Jonathan S. Weiss, MD

Adjunct Assistant Clinical Professor of Dermatology
Emory University School of Medicine
Atlanta, GA
President & Co-Managing Partner
Georgia Dermatology Partners
(Formerly, Gwinnett Dermatology, PC)

Watch Now

You May Also Like

Journal of Drugs in Dermatology JDD featuring Increased Risk of Skin Cancers in Certain Occupations

Increased Risk of Skin Cancers in Certain Occupations

| Featured Articles, Latest News, Skin Cancer | No Comments
Occupational Hazards and Skin Cancer: Why Dermatologists Must Lead on Outdoor Worker Protection Have you read the latest review from the Journal of Drugs in Dermatology examining the hidden skin…

Author Spotlight: Robert Adler BA

| Author Spotlight, Featured Articles, Latest News, Psoriasis | No Comments
Check Out JDD’s Latest Author Spotlight Our current Author Spotlight features Robert Adler BA, one of the co-authors for Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors…

Photodistributed Hyperpigmentation Associated With COVID-19 Vaccination

| COVID 19, Dyspigmentation, Featured Articles, Latest News | No Comments
From the JDD Vault: Case Report on Post-COVID-19 Vaccine Photodistributed Hyperpigmentation Cutaneous reactions and rare dermatologic manifestations linked to COVID-19 vaccination remain a trending topic of discussion among clinicians. In…

Leave a Reply